Cargando…

Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes

BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing blad...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ji-Qing, Salas, Lucas A., Wiencke, John K., Koestler, Devin C., Molinaro, Annette M., Andrew, Angeline S., Seigne, John D., Karagas, Margaret R., Kelsey, Karl T., Christensen, Brock C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543967/
https://www.ncbi.nlm.nih.gov/pubmed/37527159
http://dx.doi.org/10.1158/1055-9965.EPI-23-0331
_version_ 1785114399514558464
author Chen, Ji-Qing
Salas, Lucas A.
Wiencke, John K.
Koestler, Devin C.
Molinaro, Annette M.
Andrew, Angeline S.
Seigne, John D.
Karagas, Margaret R.
Kelsey, Karl T.
Christensen, Brock C.
author_facet Chen, Ji-Qing
Salas, Lucas A.
Wiencke, John K.
Koestler, Devin C.
Molinaro, Annette M.
Andrew, Angeline S.
Seigne, John D.
Karagas, Margaret R.
Kelsey, Karl T.
Christensen, Brock C.
author_sort Chen, Ji-Qing
collection PubMed
description BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. METHODS: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival. RESULTS: Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93–0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23–1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04–1.41), neutrophil (HR = 1.04, 95% CI = 1.03–1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03–1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. CONCLUSIONS: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. IMPACT: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers.
format Online
Article
Text
id pubmed-10543967
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-105439672023-10-03 Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes Chen, Ji-Qing Salas, Lucas A. Wiencke, John K. Koestler, Devin C. Molinaro, Annette M. Andrew, Angeline S. Seigne, John D. Karagas, Margaret R. Kelsey, Karl T. Christensen, Brock C. Cancer Epidemiol Biomarkers Prev Research Articles BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. METHODS: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival. RESULTS: Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93–0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23–1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04–1.41), neutrophil (HR = 1.04, 95% CI = 1.03–1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03–1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. CONCLUSIONS: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. IMPACT: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers. American Association for Cancer Research 2023-10-02 2023-08-01 /pmc/articles/PMC10543967/ /pubmed/37527159 http://dx.doi.org/10.1158/1055-9965.EPI-23-0331 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Research Articles
Chen, Ji-Qing
Salas, Lucas A.
Wiencke, John K.
Koestler, Devin C.
Molinaro, Annette M.
Andrew, Angeline S.
Seigne, John D.
Karagas, Margaret R.
Kelsey, Karl T.
Christensen, Brock C.
Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title_full Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title_fullStr Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title_full_unstemmed Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title_short Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
title_sort genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543967/
https://www.ncbi.nlm.nih.gov/pubmed/37527159
http://dx.doi.org/10.1158/1055-9965.EPI-23-0331
work_keys_str_mv AT chenjiqing genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT salaslucasa genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT wienckejohnk genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT koestlerdevinc genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT molinaroannettem genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT andrewangelines genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT seignejohnd genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT karagasmargaretr genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT kelseykarlt genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes
AT christensenbrockc genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes